Skip to main content
Premium Trial:

Request an Annual Quote

Jimmy Lin

Freenome has appointed Cheng-Ho Jimmy Lin, as its chief scientific officer, with responsibilities for scientific strategy, research operations, and growing the company’s scientific team. Prior to joining the private sector, Lin led the intramural clinical genomics program at the National Cancer Institute at the National Institutes of Health. At Johns Hopkins and Washington University in St Louis, he also spearheaded the computational analyses of exome sequencing studies in multiple cancer types.

Lin's most recent role was CSO for oncology at Natera, where he drove the development and launch of that firm's blood-based assays for cancer monitoring residual disease detection. He holds an MD and PhD in cellular and molecular medicine and a Masters in health sciences in bioinformatics from Johns Hopkins School of Medicine.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.